R&D expense · 2011–2025
Angiodynamics R&D expense
$29.4M+12.3% · FY2025
Angiodynamics (ANGO) reported $29.4M in R&D expense for fiscal 2025, +12.3% year on year.
| Fiscal year | R&D expense | Change | Filing |
|---|---|---|---|
| FY20252026-05-31 | $29.4M | +12.3% | Open → |
| FY20242025-05-31 | $26.2M | −16.8% | Open → |
| FY20232024-05-31 | $31.5M | +5.5% | Open → |
| FY20222023-05-31 | $29.9M | −2.8% | Open → |
| FY20212022-05-31 | $30.7M | −15.5% | Open → |
| FY20202021-05-31 | $36.4M | +22.6% | Open → |
| FY20192020-05-31 | $29.7M | +5.0% | Open → |
| FY20182019-05-31 | $28.3M | +16.1% | Open → |
| FY20172018-05-31 | $24.3M | +0.8% | Open → |
| FY20162017-05-31 | $24.1M | −3.6% | Open → |
| FY20152016-05-31 | $25.1M | −5.8% | Open → |
| FY20142015-05-31 | $26.6M | −5.4% | Open → |
| FY20132014-05-31 | $28.1M | +7.8% | Open → |
| FY20122013-05-31 | $26.1M | +27.2% | Open → |
| FY20112012-05-31 | $20.5M | — | Open → |
R&D expense — Research and development expense is what the company charged to R&D in the income statement for the year. Most companies report no R&D at all — the line is absent rather than zero — so this ranking covers the roughly 40% of filers that do.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2011–2025 compound annual growth +2.6%
R&D expense at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Angiodynamics R&D expense |url=https://companiesranked.com/en/company/angiodynamics/research-and-development-expense |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Angiodynamics R&D expense. CompaniesRanked. https://companiesranked.com/en/company/angiodynamics/research-and-development-expenseBibTeX
@misc{companiesranked-en-company-angiodynamics-research-and-development-expense-2026,
author = {{CompaniesRanked}},
title = {{Angiodynamics R\&D expense}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/angiodynamics/research-and-development-expense}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001628280-26-048138 · July 14, 2026
{{cite web |title=Angiodynamics R&D expense — 10-K (0001628280-26-048138) |url=https://www.sec.gov/Archives/edgar/data/1275187/000162828026048138/ango-20260531.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-07-14}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.